Regulation and Challenges of Biosimilars in European Union

Author(s): Vikram, Aakash Deep*, Manita.

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 6 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Biological products comprise the most complex and diverse types of drugs that are made by living cells. The use of biological products has increased significantly in recent decades and has contributed significantly to improving the efficacy of treatment in many diseases. Patent protection for pharmaceutical products, including biological products, generally expires about 20 years after development. Expiration of patents of biological innovative medicines allows regulatory authorities to approve copies of biological medicines, such as medicines called similar biological products (biosimilar) and to enter in clinical use. Biosimilar products are comparable but not identical with innovator biological products and are not a generic version of the innovator biological product. While biosimilars are subjected to rigorous characterization and clinical trials to demonstrate their safety and efficacy, in the case of biosimilars certain regulatory requirements apply for registration. Biosimilars are very complex and large molecules and minor changes in the manufacturing process can have important implications in their safety and efficacy profiles. To ensure that biosimilar reaches their potential in clinical application, intensive Pharmacovigilance system and risk management plan must be established to demonstrate the true similarity between the biosimilar products and original biological products. Biosimilars are part of the growing sector of the pharmaceutical industry and normally used by human beings since manufacturers of biosimilars face some challenges in regulatory approval and manufacturing of biosimilars in the European Union.

Objectives: The current manuscript will provide the information regarding the regulation of biosimilar products with guidelines and challenges faced by manufacturers during approved and manufacturing of biosimilar products in the European Union. This manuscript also provides the status of approved and rejected biosimilars by EMA (European Medicine Agency).

Conclusion: Biosimilars may reduce costs when patent protection of biological products expires and compared to the original products, savings are not as large as seen with traditional generics. In the coming years, there will be an increasing number of biological and biosimilar products available on the market, highlighting the need for specific short and long term post-marketing surveillance programs for these medicines. It is essential to understand how the concept of compatibility, interchangeability will be managed and regulated in the future. An important aspect for future a high quality, clinical and non-clinical studies will be conducted to evaluate the safety and efficacy of biosimilars. Scientific guidelines on biosimilar issued by the EMA (European Medicine Agency) that established a process to demonstrate the similarity between a biosimilar product and the innovator reference product.

Keywords: Regulation, European Union, challenges, regulation, biosimilars, therapeutic.

[1]
Aapro M, Krendyukov A, Höbel N, Seidl A, Gascón P. Development and 10-year history of a biosimilar: The example of Binocrit®. Ther Adv Med Oncol 2018.101758835918768419
[http://dx.doi.org/10.1177/1758835918768419] [PMID: 29707043]
[2]
Pharma research progress hope: Biosimilars 101. 2015. Available from:http://phrma-docs.phrma.org/sites/default/files/pdf/Biosimilars_101.pdf
[3]
Gámez-Belmonte R, Hernández-Chirlaque C, Arredondo-Amador M, et al. Biosimilars: Concepts and controversies. Pharmacol Res 2018; 133: 251-64.
[http://dx.doi.org/10.1016/j.phrs.2018.01.024] [PMID: 29428205]
[4]
Emmanouilides CE, Karampola MI, Beredima M. Biosimilars: Hope and concern. J Oncol Pharm Pract 2016; 22(4): 618-24.
[http://dx.doi.org/10.1177/1078155215603232] [PMID: 26391898]
[5]
Minghetti P, Rocco P, Del Vecchio L, Locatelli F. Biosimilars and regulatory authorities. Nephron Clin Pract 2011; 117(1): 1-7.
[http://dx.doi.org/10.1159/000319640] [PMID: 20689318]
[6]
Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng 2017; 114(12): 2696-705.
[http://dx.doi.org/10.1002/bit.26438] [PMID: 28842986]
[8]
European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications. 2019. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-similar-biological-medicinal_en-0.pdf
[9]
Process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. 2019. Available:https://www.medicinesforeurope.com/wp-content/uploads/2016/03/biosimilars_report_en.pdf
[10]
Abraham J. Developing oncology biosimilars: An essential approach for the future. Semin Oncol 2013; 40(Suppl. 1): 5-24.
[http://dx.doi.org/10.1053/j.seminoncol.2013.09.015] [PMID: 24267944]
[11]
Windisch A. Biosimilars versus originators: Similarities and differences from development to approval 2015; 10(6): 1-10.
[http://dx.doi.org/10.2217/ijr.15.49]
[12]
Daller J. Biosimilars: A consideration of the regulations in the United States and European Union. Regul Toxicol Pharmacol 2016; 76: 199-208.
[http://dx.doi.org/10.1016/j.yrtph.2015.12.013] [PMID: 26732800]
[13]
Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol 2015; 8(5): 649-59.
[http://dx.doi.org/10.1586/17512433.2015.1071188] [PMID: 26294076]
[14]
Knezevic I, Sheets R. Biosimilars Fundamentals of biologicals regulation. 1st ed. Academic Press 2018; pp. 345-58.
[15]
Grozdanova A, Netkovska KA, Sterjev Z, et al. Biosimilar medical products - licensing, pharmacovigilance and interchangeability. Prilozi (Makedon Akad Nauk Umet Odd Med Nauki) 2016; 37(1): 27-36.
[http://dx.doi.org/10.1515/prilozi-2016-0006] [PMID: 27442414]
[16]
Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 2014; 15(13): e594-605.
[http://dx.doi.org/10.1016/S1470-2045(14)70365-1] [PMID: 25456378]
[17]
Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: Development and evolution of the regulatory pathways. Drug Des Devel Ther 2017; 11: 1509-15.
[http://dx.doi.org/10.2147/DDDT.S130318] [PMID: 28553082]
[18]
Windisch J. Biosimilars versus originators: Similarities and differences from development to approval. Int J Clin Rheumatol 2015; 10(6): 501-10.
[http://dx.doi.org/10.2217/ijr.15.49]
[19]
Understanding key differences between biosimilars and small molecule generics. 2019. Available from:https://pdfs.semanticscholar.org/c3e4/835dc866f5c7ad132d85497b83247b6acc63.pdf
[20]
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (revision 1). 2019. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf
[21]
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. 2019. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
[22]
Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: Current status and future challenges. BioDrugs 2013; 27(3): 203-11.
[http://dx.doi.org/10.1007/s40259-013-0020-y] [PMID: 23553340]
[23]
Tsiftsoglou AS, Trouvin JH, Calvo G, Ruiz S. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe. BioDrugs 2014; 28(6): 479-86.
[http://dx.doi.org/10.1007/s40259-014-0109-y] [PMID: 25391420]
[24]
Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived. Rituximab Arthritis (Egypt) 2018; 18: 1-6.
[http://dx.doi.org/10.1155/2018/3762864] [PMID: 29765782]
[25]
Calvo B, Martinez-Gorostiaga J, Echevarria E. The surge in biosimilars: Considerations for effective pharmacovigilance and EU regulation. Ther Adv Drug Saf 2018; 9(10): 601-8.
[http://dx.doi.org/10.1177/2042098618790442] [PMID: 30283628]
[27]
Biosimilars in the EU: Information guide for healthcare professionals. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
[29]
European Medical Agency. Applying for EU maketing authorisation. 2019. Available from: https://www.ema.europa.eu/en/documents/leaflet/applying-european-union-marketing-authorisation-medicinal-products-human-use_en.pdf
[30]
Jawahar N, Shrivastava N, Ramachandran A, Priyadharshini BR. Procedures and applications for marketing authorisation of medicinal products in European Union. J of Pharma Sci and Res 2015; 7(4): 219.
[32]
Socinski M, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. InMAbs 2015; 7(2): 286-93.
[34]
Zuñiga L, Calvo B. Biosimilars: Pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010; 19(7): 661-9.
[http://dx.doi.org/10.1002/pds.1948] [PMID: 20583204]
[35]
Begoña C, Leyre Z. Risk Management Plan and Pharmacovigilance System Biopharmaceuticals: Biosimilars. 2019. [cited: 15 April 2019]. Available from:https://www.intechopen.com/books/risk-management-trends/risk-management-plan-and-pharmacovigilance-system-biopharmaceuticals-biosimilars
[36]
Calvo B, Zuñiga LE. U’s new pharmacovigilance legislation: considerations for biosimilars. Drug Saf 2014; 37(1): 9-18.
[http://dx.doi.org/10.1007/s40264-013-0121-z] [PMID: 24190573]
[38]
Essential medicines and health products: Pharmacovigilance 2019. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
[39]
Leung LK, Mok K, Liu C, Chan SL. What do oncologists need to know about biosimilar products? Chin J Cancer 2016; 35(1): 91.
[http://dx.doi.org/10.1186/s40880-016-0151-x] [PMID: 27733189]
[40]
Mielke J, Jilma B, Koenig F, Jones B. Clinical trials for authorized biosimilars in the European Union: A systematic review. Br J Clin Pharmacol 2016; 82(6): 1444-57.
[http://dx.doi.org/10.1111/bcp.13076] [PMID: 27580073]
[41]
Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: How can payers get long-term savings? Pharmacoeconomics 2016; 34(6): 609-16.
[http://dx.doi.org/10.1007/s40273-015-0380-x] [PMID: 26792791]
[43]
Stevenson JG, Popovian R, Jacobs I, Hurst S, Shane LG. Biosimilars: Practical considerations for pharmacists. Ann Pharmacother 2017; 51(7): 590-602.
[http://dx.doi.org/10.1177/1060028017690743] [PMID: 28176529]
[44]
Simoens S, Huys I. Market entry of biosimilar low-molecular-weight heparins in Europe: Opportunities and challenges. Semin Thromb Hemost 2013; 39(3): 250-7.
[PMID: 23235959]
[45]
Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: The case of biosimilar monoclonal antibodies. Front Pharmacol 2016; 7: 193.
[http://dx.doi.org/10.3389/fphar.2016.00193] [PMID: 27445826]
[46]
Barriers to uptake of biosimilars identified in Belgium. PharmacoEconomics & outcomes news 2014; 703(1): 4.
[http://dx.doi.org/10.1007/s40274-014-1254-8]
[47]
Biosimilars: Prospects and challenges. 2019. Available from: https://resultshealthcare.com/insight/biosimilars-prospects-and-challenges/
[48]
Posts,V. (2019). Top-10 Medical Devices Companies 2018 - IgeaHub. [cited: 11 February 2019]. Available at:https://www.igeahub.com/2018/08/03/top-10-medical-devices-companies-2018/
[49]
Biosimilar substitution in Europe. 2019. Available from: http://www.gabionline.net/Reports/Biosimilar-substitution-in-Europe
[50]
Tsuruta LR, Lopes dos Santos M, Moro AM. Biosimilars advancements: Moving on to the future. Biotechnol Prog 2015; 31(5): 1139-49.
[http://dx.doi.org/10.1002/btpr.2066] [PMID: 25708573]
[51]
Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. MAbs 2015; 7(2): 286-93.
[http://dx.doi.org/10.1080/19420862.2015.1008346] [PMID: 25621390]
[52]
Tkaczuk KH, Jacobs IA. Biosimilars in oncology: From development to clinical practice 2014; 41: S1- 12.
[http://dx.doi.org/10.1053/j.seminoncol.2014.03.008]
[53]
Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010; 28(1): 28-31.
[http://dx.doi.org/10.1038/nbt0110-28] [PMID: 20062035]
[54]
Biosimilars approvals in Europe. 2017. Available from: https://www.biologicsblog.com/2017-biosimilar-approvals-in-europe/
[55]
Watch B. European biosimilars approval updates: Adalimumab, pegfilgratism. 2018. Available from: https://www.bigmoleculewatch.com/2018/09/26/european-biosimilar-approval-updates-adalimumab-pegfilgrastim/
[56]
Mehr S, Mehr V. Comparing biosimilars approvals progress by the FDA and EMA Available from: https://biosimilarsrr.com/2019/02/27/comparing-biosimilar-approval-progress-by-the-fda-and-ema/
[57]
Biosimilars approved in Europe. 2018. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 3
Year: 2019
Page: [192 - 211]
Pages: 20
DOI: 10.2174/2213476X06666190906152404

Article Metrics

PDF: 10
HTML: 4